# The Confirmatory Olmesartan Plaque Regression Study

> **NCT01132768** · PHASE4 · TERMINATED · sponsor: **Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company** · enrollment: 114 (actual)

## Conditions studied

- Essential Hypertension
- Carotid Plaque

## Interventions

- **DRUG:** Atenolol
- **DRUG:** olmesartan medoxomil

## Key facts

- **NCT ID:** NCT01132768
- **Lead sponsor:** Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 114 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132768, "The Confirmatory Olmesartan Plaque Regression Study". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01132768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*